Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab added to VCD for transplant-ineligible newly diagnosed multiple myeloma
ACTRN12617000202369Phase 2Completed
- Sponsor
- Alfred Health
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Alfred Health. Primary endpoint: Progression-free survival. Started Aug 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12617000202369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000202369.